Xerava (eravacycline) to treat complex celiac infections: a Phase III clinical trial in China is to be conducted.

Infections in the abdominal cavity are usually caused by inflammation or rupture of the gastrointestinal tract.
, celiac infections can also come from the urinary tract or the female reproductive tract.
celiac infections are usually caused by a variety of microorganisms and can cause abdominal abscesses or secondary perititis, which can be widespread or limited (cellulitis).
pharmaceutical company Everest Pharmaceuticals recently announced that it has completed its Phase III clinical trial of eravacycline to treat patients with complex cIAI infections in China.
Xerava (eravacycline) is a new, fully synthetic broad-spectrum gastrointestinal cyclin.
in two previous key global studies, Xerava has good tolerance in cIAI patients and is statistically no less statistically inferior to two widely used drugs (ertapenem and meropenem).
two studies led to Xerava's approval in the United States, the European Union and Singapore.
results of the China trial are expected to be released in the fourth quarter of 2020 and will support Everest Pharmaceuticals in submitting applications for new drugs in China.
First China Phase III clinical trial is an important milestone for Everest Medicines," said Sunny Zhu, chief medical officer for Infectious Diseases at Everest Medicines.
Xerava represents an important new treatment that can be used to deal with complex infections."
.